Latest Safety News

EV Resources has cleared a key technical review of its Tecomatlán processing plant in Mexico, setting the stage for near-term antimony concentrate production and pilot testing for its Los Lirios project.

Neurizon Therapeutics has secured FDA clearance for its lead drug candidate NUZ-001 to enter the HEALEY ALS Platform Trial, marking a key regulatory milestone and setting the stage for patient enrollment in early 2026.

Lindian Resources has awarded all major non-process infrastructure contracts for its Kangankunde Rare Earths Project in Malawi, marking a pivotal step toward first production in late 2026. Construction is underway with strong schedule confidence and capital discipline.

InhaleRx advances its clinical pipeline with a new oral treatment for resistant depression and plans a strategic rebrand to Nexalis Therapeutics, signaling a broader focus beyond inhaled therapies.

Beacon Minerals reports strong assay results from its ongoing drill program at the Iguana Deposit, alongside securing vital land use and mining approvals, advancing the Lady Ida Project towards production.

Immutep has struck a strategic licensing deal with Dr. Reddy’s, granting rights to commercialise its novel cancer immunotherapy Eftilagimod Alfa across key emerging markets. The agreement includes a $20 million upfront payment and potential milestones exceeding $349 million.

Memphasys is intensifying its direct sales efforts for the Felix™ sperm-selection device across key Middle East IVF clinics, positioning for rapid market activation upon CE Mark approval expected early 2026.

Meteoric Resources is poised for a critical environmental milestone as the Preliminary Environmental Licence for its Caldeira Rare Earth Project is set for approval at the upcoming COPAM meeting. This step could unlock the path to construction and keep the project timeline intact.

Chimeric Therapeutics has won FDA Orphan Drug Designation for its CHM CDH17 CAR-T therapy targeting gastric cancer, advancing its clinical development with regulatory incentives and potential market exclusivity.

Telix Pharmaceuticals has dosed the first patient in the randomized expansion phase of its pivotal ProstACT Global Phase 3 trial for TLX591, targeting advanced prostate cancer. The trial is expanding globally, with regulatory submissions underway in the US and Europe.

DorsaVi reports significant progress in its resistive RAM (RRAM) development, optimizing memory technology for integration with neuromorphic computing at the 22nm technology node. This advancement positions the company to deliver energy-efficient edge-AI solutions for wearables, robotics, and industrial safety.

Anteris Technologies has secured regulatory green lights for its pivotal PARADIGM trial and raised $25.2 million in capital, advancing its innovative DurAVR® transcatheter heart valve towards commercialisation.